Inflammation, genes and zinc in Alzheimer's disease

Abdullah, 2006, The cyclooxygenase 2-765 C promoter allele is a protective factor for Alzheimer's disease, Neurosci. Lett., 395, 240, 10.1016/j.neulet.2005.10.090 Aisen, 2003, Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial, JAMA, 289, 2819, 10.1001/jama.289.21.2819 Akiyama, 2000, Inflammation and Alzheimer's disease, Neurobiol. Aging, 21, 383, 10.1016/S0197-4580(00)00124-X Albert, 2001, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study, JAMA, 286, 64, 10.1001/jama.286.1.64 Allan, 2005, Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias, J. Am. Geriatr. Soc., 53, 1681, 10.1111/j.1532-5415.2005.53552.x Aronson, 1991, Dementia. Age-dependent incidence, prevalence, and mortality in the old, Arch. Intern. Med., 151, 989, 10.1001/archinte.151.5.989 Atwood, 2003, Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta, Brain Res. Brain Res. Rev., 43, 1, 10.1016/S0165-0173(03)00174-7 Auld, 2003, Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies, Prog. Neurobiol., 3, 209 Bagnoli, 2007, Association of IL10 promoter polymorphism in Italian Alzheimer's disease, Neurosci. Lett., 418, 262, 10.1016/j.neulet.2007.03.030 Bao, 2003, Zinc modulates mRNA levels of cytokines, Am. J. Physiol: Endocrinol. Metab., 285, E1095-1020, 10.1152/ajpendo.00545.2002 Bird, 2005, Genetic factors in Alzheimer's disease, N. Engl. J. Med., 352, 862, 10.1056/NEJMp058027 Blain, 2004, Cholesterol homeostasis and the pathophysiology of Alzheimer's disease, Expert Rev. Neurother., 4, 823, 10.1586/14737175.4.5.823 Borovikova, 2000, Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin, Nature, 405, 458, 10.1038/35013070 Breitner, 2003, NSAIDs and Alzheimer's disease: how far to generalise from trials?, Lancet Neurol., 2, 527, 10.1016/S1474-4422(03)00498-8 Cacquevel, 2004, Cytokines in neuroinflammation and Alzheimer's disease, Curr Drug Targets, 5, 529, 10.2174/1389450043345308 Camandola, 2007, NF-kappa B as a therapeutic target in neurodegenerative diseases, Expert Opin Ther Targets, 11, 123, 10.1517/14728222.11.2.123 Campion, 1999, Early-onset autosomal dominant Alzheimer's disease: prevalence, genetic heterogeneity, and mutation spectrum, Am. J. Hum. Genet., 65, 664, 10.1086/302553 Candore, 2007, Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: a pharmacogenomic approach, Mech. Ageing Dev., 128, 67, 10.1016/j.mad.2006.11.013 Candore, 2006, Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer's disease, Ann. N. Y. Acad. Sci., 1089, 472, 10.1196/annals.1386.008 Caruso, 2005, Inflammation and life-span, Science, 307, 208, 10.1126/science.307.5707.208 Chong, 2002, High-density lipoprotein cholesterol and the role of statins, Circ. J., 66, 1037, 10.1253/circj.66.1037 Colton, 2004, APOE genotype-specific differences in human and mouse macrophage nitric oxide production, J. Neuroimmunol., 147, 62, 10.1016/j.jneuroim.2003.10.015 Cordle, 2005, 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses, J. Neurosci., 25, 299, 10.1523/JNEUROSCI.2544-04.2005 Cordy, 2006, The involvement of lipid rafts in Alzheimer's disease, Mol. Membr. Biol., 23, 111, 10.1080/09687860500496417 Del Bo, 1995, Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures, Neurosci. Lett., 188, 70, 10.1016/0304-3940(95)11384-9 Dickson, 1988, Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques, Am. J. Pathol., 132, 86 Etminan, 2003, Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies, BMJ, 327, 128, 10.1136/bmj.327.7407.128 Fassbender, 2000, Alzheimer's disease: an inflammatory disease?, Neurobiol. Aging, 21, 433, 10.1016/S0197-4580(00)00147-0 Finch, 2005, Developmental origins of aging in brain and blood vessels: an overview, Neurobiol. Aging, 26, 281, 10.1016/j.neurobiolaging.2004.03.015 Finch, 2007, Systemic inflammation, infection, ApoE alleles, and Alzheimer's disease: a position paper, Curr. Alzheimer Res., 4, 185, 10.2174/156720507780362254 Finch, 2002, Lipoprotein genes and diet in the evolution of human intelligence and longevity Findeis, 2007, The role of amyloid beta peptide 42 in Alzheimer's disease, Pharmacol. Ther., 116, 266, 10.1016/j.pharmthera.2007.06.006 Frazzini, 2006, Oxidative stress and brain aging: is zinc the link?, Biogerontology, 7, 307, 10.1007/s10522-006-9045-7 Frederickson, 1994, Zinc-containing neurons, Biol. Signals, 3, 127, 10.1159/000109536 Frederickson, 2005, The neurobiology of zinc in health and disease, Nat. Rev., Neurosci., 6, 449, 10.1038/nrn1671 Frederickson, 2000, Importance of zinc in the central nervous system: the zinc-containing neuron, J. Nutr., 130, 1471, 10.1093/jn/130.5.1471S Friedlander, 2003, Mechanisms of disease: apoptosis and caspases in neurodegenerative diseases, N. Engl. J. Med., 348, 1365, 10.1056/NEJMra022366 Ghribi, 2006, Deposition of iron and betaamyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets, J. Neurochem., 99, 438, 10.1111/j.1471-4159.2006.04079.x Griffin, 2002, Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease, J. Leukoc. Biol., 72, 233, 10.1189/jlb.72.2.233 Griffin, 1998, Glial-neuronal interactions in Alzheimer's disease, the potential role of a ‘cytokine cycle’ in disease progression, Brain Pathol., 8, 65, 10.1111/j.1750-3639.1998.tb00136.x Guan, 2004, Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease, J. Neurochem., 74, 237, 10.1046/j.1471-4159.2000.0740237.x Halliday, 2000, Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms, Clin. Exp. Pharmacol. Physiol., 27, 1, 10.1046/j.1440-1681.2000.03200.x Heyninck, 2005, A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions, Trends Biochem. Sci., 30, 1, 10.1016/j.tibs.2004.11.001 Hidalgo, 2001, Roles of the metallothionein family of proteins in the central nervous system, Brain Res. Bull., 55, 133, 10.1016/S0361-9230(01)00452-X Huang, 1997, Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors, J. Biol. Chem., 272, 26464, 10.1074/jbc.272.42.26464 Hutton, 1998, Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17, Nature, 393, 702, 10.1038/31508 Imahara, 2004, Genetic determinants of the inflammatory response, Curr. Opin. Crit. Care, 10, 318, 10.1097/01.ccx.0000140942.42247.7e Jofre-Monseny, 2007, Effects of apoE genotype on macrophage inflammation and heme oxygenase-1 expression, Biochem. Biophys. Res. Commun., 357, 319, 10.1016/j.bbrc.2007.03.150 Jofre-Monseny, 2007, Differential effects of apolipoprotein E3 and E4 on markers of oxidative status in macrophages, Br. J. Nutr., 97, 864, 10.1017/S0007114507669219 Kagi, 1988, Biochemistry of metallothionein, Biochemistry, 27, 8509, 10.1021/bi00423a001 Kihara, 1998, Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity, Brain Res., 792, 331, 10.1016/S0006-8993(98)00138-3 Kihara, 1997, Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity, Ann. Neurol., 42, 159, 10.1002/ana.410420205 Kivipelto, 2006, Cholesterol as a risk factor for Alzheimer's disease — epidemiological evidence, Acta Neurol. Scand., 114, 50, 10.1111/j.1600-0404.2006.00685.x Kuller, 2007, Statins and dementia, Curr. Atheroscler. Rep., 9, 154, 10.1007/s11883-007-0012-9 Kwon, 2000, Tau polymorphisms are not associated with Alzheimer's disease, Neurosci. Lett., 284, 77, 10.1016/S0304-3940(00)00972-1 Licastro, 2007, Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation, Neurobiol. Aging, 28, 1637, 10.1016/j.neurobiolaging.2006.07.007 Lindberg, 2005, Cytokine production by a human microglial cell line: effects of beta-amyloid and alpha-melanocyte-stimulating hormone, Neurotox. Res., 8, 267, 10.1007/BF03033980 Ma, 2007, Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer's disease in Chinese, Neurobiol. Aging Mahley, 2000, Apolipoprotein E: far more than a lipid transport protein, Annu. Rev. Genomics Hum. Genet., 1, 507, 10.1146/annurev.genom.1.1.507 Maret, 2000, The function of zinc metallothionein: a link between cellular zinc and redox state, J. Nutr., 130, 1455S, 10.1093/jn/130.5.1455S Martin, 2006, Vitamins for the elderly: from A to zinc, Consult. Pharm., 21, 450, 10.4140/TCP.n.2006.450 Martin-Ruiz, 1999, Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease, J. Neurochem., 4, 1635 Maurer, 1997, Auguste D and Alzheimer's disease, Lancet, 349, 1546, 10.1016/S0140-6736(96)10203-8 McGeer, 1996, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies, Neurology, 47, 425, 10.1212/WNL.47.2.425 McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 Meyer, 1998, APOE genotype predicts when—not whether—one is predisposed to develop Alzheimer's disease, Nat. Genet., 119, 321, 10.1038/1206 Minoretti, 2006, Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease, Neurosci. Lett., 391, 147, 10.1016/j.neulet.2005.08.047 Misonou, 2000, Oxidative stress induces intracellular accumulation of amyloid beta-protein(Abeta) in human neuroblastoma cells, Biochemistry, 13, 6951, 10.1021/bi000169p Mitchell, 2003, Acute and chronic inflammation Mocchegiani, 2006, Nutrient-gene interaction in ageing and successful ageing. A single nutrient (zinc) and some target genes related to inflammatory/immune response, Mech. Ageing Dev., 127, 517, 10.1016/j.mad.2006.01.010 Mocchegiani, 2000, Zinc and immunoresistance to infection in aging: new biological tools, Trends Pharmacol. Sci., 21, 205, 10.1016/S0165-6147(00)01476-0 Morgan, 2007, Association studies of 23 positional/functional candidate genes on chromosome 10 in late-onset Alzheimer's disease, Am. J. Med. Genet. B Neuropsychiatr. Genet., 144, 762, 10.1002/ajmg.b.30509 Moroni, 2005, Interrelationship among neutrophil efficency, inflammation, antioxidant activity and Zinc pool in very old age, Biogerontology, 6, 271, 10.1007/s10522-005-2625-0 Mrak, 2005, Glia and their cytokines in progression of neurodegeneration, Neurobiol. Aging, 26, 349, 10.1016/j.neurobiolaging.2004.05.010 Mrak, 1995, Glial cytokines in Alzheimer's disease: review and pathogenic implications, Hum. Pathos., 26, 816, 10.1016/0046-8177(95)90001-2 Newman, 2007, Alzheimer disease: amyloidogenesis, the presenilins and animal models, Biochim. Biophys. Acta., 1772, 285, 10.1016/j.bbadis.2006.12.001 Nussbaum, 2003, Genomic medicine: Alzheimer's disease and Parkinson's disease, N. Engl. J. Med., 348, 1356, 10.1056/NEJM2003ra020003 Opipari, 1990, The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein, J. Biol. Chem., 265, 14705, 10.1016/S0021-9258(18)77165-2 Porcellini, 2007, The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration, Neurosci. Lett., 416, 66, 10.1016/j.neulet.2007.01.046 Priller, 2006, Synapse formation and function is modulated by the amyloid precursor protein, J. Neurosci., 26, 7212, 10.1523/JNEUROSCI.1450-06.2006 Qu, 2001, 5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease, J. Neuropsychiatry Clin. Neurosci., 13, 304, 10.1176/appi.neuropsych.13.2.304 Rainero, 2004, Association between the interleukin-1alpha gene and Alzheimer's disease, a meta-analysis, Neurobiol. Aging, 25, 1293, 10.1016/j.neurobiolaging.2004.02.011 Reiman, 2007, GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers, Neuron, 54, 713, 10.1016/j.neuron.2007.05.022 Reines, 2004, Rofecoxib protocol 091 study group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology, 62, 66, 10.1212/WNL.62.1.66 Religa, 2006, Elevated cortical zinc in Alzheimer's disease, Neurology, 67, 69, 10.1212/01.wnl.0000223644.08653.b5 Ringheim, 1998, Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex, Brain Res. Mol. Brain Res., 55, 35, 10.1016/S0169-328X(97)00356-2 Rink, 2000, Zinc-altered immune function and cytokine production, J. Nutr., 130, 1407S, 10.1093/jn/130.5.1407S Ritchie, 2004, Metal-protein attenuating compounds and Alzheimer's disease, Expert Opin. Investig. Drugs, 13, 1585, 10.1517/13543784.13.12.1585 Roberson, 2007, Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model, Science, 316, 750, 10.1126/science.1141736 Rockwood, 2002, Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people, Arch. Neurol., 59, 223, 10.1001/archneur.59.2.223 Rogers, 1988, Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease., Neurobiol. Aging, 9, 339, 10.1016/S0197-4580(88)80079-4 Roy, 2002, Impacts of transcriptional regulation on aging and senescence, Ageing Res. Rev., 1, 367, 10.1016/S1568-1637(02)00006-5 Sambamurti, 1999, Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein, Biol. Chem., 274, 26810, 10.1074/jbc.274.38.26810 Schmidt, 2002, Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study, Ann. Neurol., 52, 168, 10.1002/ana.10265 Selkoe, 2001, Alzheimer's disease: genes, proteins, and therapy, Physiol. Rev., 81, 741, 10.1152/physrev.2001.81.2.741 Seshadri, 1995, Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know, Arch. Neurol., 52, 1074, 10.1001/archneur.1995.00540350068018 Sheng, 2003, Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice, Neurobiol. Dis., 14, 133, 10.1016/S0969-9961(03)00069-X Slomianka, 1992, Neurons of origin of zinc-containing pathways and the distribution of zinc-containing boutons in the hippocampal region of the rat, Neuroscience, 48, 325, 10.1016/0306-4522(92)90494-M Smith, 2002, Apolipoproteins and aging: emerging mechanisms, Ageing Res. Rev., 1, 345, 10.1016/S1568-1637(02)00005-3 Stankovic, 2007, Metallothioneins I and II: neuroprotective significance during CNS pathology, Int. J. Biochem. Cell Biol., 39, 484, 10.1016/j.biocel.2006.09.010 Strittmatter, 1996, Apolipoprotein E and Alzheimer's disease, Annu. Rev. Neurosci., 19, 53, 10.1146/annurev.ne.19.030196.000413 Stüve, 2003, Statins as potential therapeutic agents in neuroinflammatory disorders, Curr. Opin. Neurol., 16, 393, 10.1097/00019052-200306000-00021 Sviridov, 2007, Statins and metabolism of high density lipoprotein, Cardiovasc. Hematol. Agents Med. Chem., 5, 215, 10.2174/187152507781058672 Takeda, 2000, Movement of zinc and its functional significance in the brain, Brain Res. Brain Res. Rev., 34, 137, 10.1016/S0165-0173(00)00044-8 Tohgi, 1998, Age related changes in nicotinic acetylcholine receptor subunits α4 and β2 messenger RNA expression in post-mortem human frontal cortex and hippocampus, Neurosci. Lett., 245, 139, 10.1016/S0304-3940(98)00205-5 Town, 2005, The microglial “activation” continuum, from innate to adaptive responses, J. Neuroinflammation, 2, 24, 10.1186/1742-2094-2-24 Tsoi, 2007, Apoprotein E isoform-dependent expression and secretion of pro-inflammatory cytokines TNF-alpha and IL-6 in macrophages, Arch. Biochem. Biophys., 460, 33, 10.1016/j.abb.2007.01.019 Tuppo, 2005, The role of inflammation in Alzheimer's disease, Int. J. Biochem. Cell Biol., 37, 289, 10.1016/j.biocel.2004.07.009 Vasto, 2006, The nACHR4 594C/T polymorphism in Alzheimer's disease, Rejuvenation Res., 9, 107, 10.1089/rej.2006.9.107 Vasto, 2006, Inflammation, genes and zinc in ageing and age-related diseases, Biogerontology, 7, 315, 10.1007/s10522-006-9046-6 Vasto, 2007, Zinc and inflammatory/immune response in aging, Ann. N. Y. Acad. Sci., 1100, 111, 10.1196/annals.1395.009 Vasto, 2007, Inflammatory networks in ageing, age related diseases and longevity, Mech. Ageing Dev., 128, 83, 10.1016/j.mad.2006.11.015 Vasto, 2007, Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision, Pharmacogenomics, 8, 1735, 10.2217/14622416.8.12.1735 Veld in t, 2001, Non steroidal anti-inflammatory drugs and the risk of Alzheimer's disease, N. Engl. J. Med., 345, 1515, 10.1056/NEJMoa010178 von Bulow, 2005, Zinc-mediated inhibition of cyclic nucleotide phosphodiesterase activity and expression suppresses TNF-alpha and IL-1 beta production in monocytes by elevation of guanosine 3′,5′-cyclic monophosphate, J. Immunol., 175, 4697, 10.4049/jimmunol.175.7.4697 Weiss, 2000, Zn(2+): a novel ionic mediator of neural injury in brain disease, Trends Pharmacol. Sci., 21, 395, 10.1016/S0165-6147(00)01541-8 Wevers, 1999, Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein, Eur. J. Neurosci, 11, 2551, 10.1046/j.1460-9568.1999.00676.x Wierzbicki, 2003, The lipid and non-lipid effects of statins, Pharmacol. Ther., 99, 95, 10.1016/S0163-7258(03)00055-X Wilson, 2003, Head injury and Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, 74, 841, 10.1136/jnnp.74.7.841 Yanagisawa, 2002, Cholesterol and pathological processes in Alzheimer's disease, J. Neurosci. Res., 70, 361, 10.1002/jnr.10348 Yao, 2004, Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits, J. Neurochem., 90, 1011, 10.1111/j.1471-4159.2004.02532.x Zhou, 2007, Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis, Dement. Geriatr. Cogn. Disord., 23, 194, 10.1159/000099037 Zipp, 2007, Impact of HMG-CoA reductase inhibition on brain pathology, Trends Pharmacol. Sci., 28, 342, 10.1016/j.tips.2007.05.001 Zoli, 1999, Increased neurodegeneration during ageing in mice lacking high affinity nicotine receptors, EMBO J., 18, 1235, 10.1093/emboj/18.5.1235